Results 1 to 10 of about 1,264,471 (268)

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas [PDF]

Zhongguo aizheng zazhi, 2023
CD30 can be expressed in a variety of lymphoma subtypes, among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones.
CD-Positive Lymphoma Pathology Expert Group
doaj   +1 more source

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

Blood Cancer Journal, 2021
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear.
Sabela Bobillo, Erel Joffe, David Sermer, Patrizia Mondello, Paola Ghione, Philip C. Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Connie L. Batlevi, Alison Moskowitz, Ariela Noy, Collette N. Owens, M. Lia Palomba, David Straus, Gottfried von Keudell, Ahmet Dogan, Andrew D. Zelenetz, Venkatraman E. Seshan, Anas Younes   +21 more
doaj   +1 more source

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

BMC Cancer, 2023
Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling   +16 more
doaj   +1 more source

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Blood Cancer Journal, 2022
Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center.
Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C. Caron, Lorenzo Falchi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Lia M. Palomba, Ildefonso Rodriguez-Rivera, David Straus, Gottfried von Keudell, Andrew D. Zelenetz, Joachim Yahalom, Ahmet Dogan, Heiko Schöder, Venkatraman E. Seshan, Gilles Salles, Anas Younes, Connie L. Batlevi   +26 more
doaj   +1 more source

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

Experimental Hematology & Oncology, 2023
Background Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitotic regulator, was highly expressed
Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Shiyu Xiao, Weilong Zhang, Mingxia Zhu, Yanfang Wang, Xiaoyan Ke, Hongmei Jing   +9 more
doaj   +1 more source

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

New England Journal of Medicine, 2020
BACKGROUND Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR)
Michael L. Wang, J. Muñoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. Mcsweeney, D. Miklos, J. Pagel, M. Kersten, N. Milpied, H. Fung, M. Topp, R. Houot, A. Beitinjaneh, W. Peng, Lianqing Zheng, J. Rossi, R. Jain, A. Rao, P. Reagan   +24 more
semanticscholar   +1 more source

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

New England Journal of Medicine, 2002
Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in
B. E. C. Oiffier, E. R. L. Epage, J. Rière, R. A. H. Erbrecht, T. Illy, R. E. B. Ouabdallah, P. Ierre, M. Orel, E. R. V. A. D. E. N. Este, G. I. S. Alles, P. H. G. Aulard, F. E. R. Eyes, C. H. G. Isselbrecht   +12 more
semanticscholar   +2 more sources

First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature [PDF]

Терапевтический архив, 2018
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen.
N G CHERNOVA, E E ZVONKOV, D S BADMAZHAPOVA, M N SINITSYNA, L A GREBENYUK, Y V SIDOROVA, I E KOSTINA, A M KOVRIGINA, T N OBUKHOVA, A B SUDARIKOV, V G SAVCHENKO   +10 more
doaj   +1 more source

Lymphoma segmentation from 3D PET-CT images using a deep evidential network [PDF]

International Journal of Approximate Reasoning, Volume 149, 2022, Pages 39-60,, 2022
An automatic evidential segmentation method based on Dempster-Shafer theory and deep learning is proposed to segment lymphomas from three-dimensional Positron Emission Tomography (PET) and Computed Tomography (CT) images. The architecture is composed of a deep feature-extraction module and an evidential layer.
arxiv   +1 more source

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]

, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander, Christoph, Renné, Hansmann, Martin L.   +2 more
core   +2 more sources